Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
University of California, Irvine
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
Seagen Inc.
Merus B.V.
Pfizer
Arvinas Inc.
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Genentech, Inc.
Brigham and Women's Hospital
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Alliance for Clinical Trials in Oncology
Amgen
xCures
Daiichi Sankyo
One-carbon Therapeutics AB
SN BioScience
University of Nebraska
Takeda
Qilu Pharmaceutical Co., Ltd.
Zhejiang University
Adela, Inc
Perspective Therapeutics
Second Life Therapeutics
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
Var2 Pharmaceuticals
GlaxoSmithKline
University of Pittsburgh
Tanabe Pharma America, Inc.
HiFiBiO Therapeutics
BicycleTx Limited
AbbVie
Actym Therapeutics, Inc.
LigaChem Biosciences, Inc.
Washington University School of Medicine
Bolt Biotherapeutics, Inc.
Travera Inc
Nurix Therapeutics, Inc.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Palleon Pharmaceuticals, Inc.